- About
- Strategic Plan
- Structure
- Governance
- Scientific divisions
- ACRF Cancer Biology and Stem Cells
- ACRF Chemical Biology
- Advanced Technology and Biology
- Bioinformatics
- Blood Cells and Blood Cancer
- Clinical Translation
- Epigenetics and Development
- Immunology
- Infectious Diseases and Immune Defence
- Inflammation
- Personalised Oncology
- Population Health and Immunity
- Structural Biology
- Ubiquitin Signalling
- Laboratory operations
- Funding
- Annual reports
- Human research ethics
- Scientific integrity
- Institute life
- Career opportunities
- Business Development
- Collaborators
- Suppliers
- Publications repository
- Awards
- Discoveries
- Centenary 2015
- History
- Contact us
- Research
- Diseases
- Cancer
- Development and ageing
- Immune health and infection
- Research fields
- Research technologies
- Research centres
- People
- Alistair Brown
- Anne-Laure Puaux
- Assoc Prof Joanna Groom
- Associate Profesor Ian Majewski
- Associate Professor Aaron Jex
- Associate Professor Andrew Webb
- Associate Professor Chris Tonkin
- Associate Professor Diana Hansen
- Associate Professor Edwin Hawkins
- Associate Professor Ethan Goddard-Borger
- Associate Professor Gemma Kelly
- Associate Professor Grant Dewson
- Associate Professor Isabelle Lucet
- Associate Professor James Vince
- Associate Professor Jason Tye-Din
- Associate Professor Jeff Babon
- Associate Professor Joan Heath
- Associate Professor John Wentworth
- Associate Professor Justin Boddey
- Associate Professor Kate Sutherland
- Associate Professor Kelly Rogers
- Associate Professor Marie-Liesse Asselin-Labat
- Associate Professor Melissa Call
- Associate Professor Misty Jenkins
- Associate Professor Nawaf Yassi
- Associate Professor Oliver Sieber
- Associate Professor Rachel Wong
- Associate Professor Rhys Allan
- Associate Professor Rosie Watson
- Associate Professor Ruth Kluck
- Associate Professor Shalin Naik
- Associate Professor Sumitra Ananda
- Associate Professor Tim Thomas
- Associate Professor Tracy Putoczki
- Chela Niall
- Deborah Carr
- Dr Alisa Glukhova
- Dr Anna Coussens
- Dr Ashley Ng
- Dr Belinda Phipson
- Dr Ben Tran
- Dr Bernhard Lechtenberg
- Dr Brad Sleebs
- Dr Drew Berry
- Dr Gwo Yaw Ho
- Dr Hamish King
- Dr Hui-Li Wong
- Dr Jacqui Gulbis
- Dr Jim Whittle
- Dr Lucy Gately
- Dr Margaret Lee
- Dr Mary Ann Anderson
- Dr Maryam Rashidi
- Dr Matthew Call
- Dr Nadia Davidson
- Dr Nadia Kershaw
- Dr Philippe Bouillet
- Dr Rebecca Feltham
- Dr Rory Bowden
- Dr Samir Taoudi
- Dr Sarah Best
- Dr Saskia Freytag
- Dr Shabih Shakeel
- Dr Sheau Wen Lok
- Dr Stephin Vervoort
- Dr Yunshun Chen
- Guillaume Lessene
- Helene Martin
- Joh Kirby
- Kaye Wycherley
- Keely Bumsted O'Brien
- Mr Simon Monard
- Mr Steve Droste
- Ms Carolyn MacDonald
- Professor Alan Cowman
- Professor Andreas Strasser
- Professor Andrew Roberts
- Professor Anne Voss
- Professor Clare Scott
- Professor Daniel Gray
- Professor David Huang
- Professor David Komander
- Professor David Vaux
- Professor Doug Hilton
- Professor Geoff Lindeman
- Professor Gordon Smyth
- Professor Ian Wicks
- Professor Ivo Mueller
- Professor James McCarthy
- Professor James Murphy
- Professor Jane Visvader
- Professor Jeanne Tie
- Professor Jerry Adams
- Professor John Silke
- Professor Ken Shortman
- Professor Leanne Robinson
- Professor Leonard C Harrison
- Professor Lynn Corcoran
- Professor Marnie Blewitt
- Professor Matthew Ritchie
- Professor Melanie Bahlo
- Professor Melissa Davis
- Professor Mike Lawrence
- Professor Nicos Nicola
- Professor Peter Colman
- Professor Peter Czabotar
- Professor Peter Gibbs
- Professor Phil Hodgkin
- Professor Sandra Nicholson
- Professor Sant-Rayn Pasricha
- Professor Seth Masters
- Professor Stephen Nutt
- Professor Suzanne Cory
- Professor Terry Speed
- Professor Tony Papenfuss
- Professor Wai-Hong Tham
- Professor Warren Alexander
- Diseases
- Education
- PhD
- Honours
- Masters
- Clinician-scientist training
- Undergraduate
- Student research projects
- A multi-pronged approach to targeting myeloproliferative neoplasms
- A new paradigm of machine learning-based structural variant detection
- A whole lot of junk or a treasure trove of discovery?
- Advanced imaging interrogation of pathogen induced NETosis
- Analysing the metabolic interactions in brain cancer
- Atopic dermatitis causes and treatments
- Boosting the efficacy of immunotherapy in lung cancer
- Building a cell history recorder using synthetic biology for longitudinal patient monitoring
- Characterisation of malaria parasite proteins exported into infected liver cells
- Deciphering the heterogeneity of the tissue microenvironment by multiplexed 3D imaging
- Defining the mechanisms of thymic involution and regeneration
- Delineating the molecular and cellular origins of liver cancer to identify therapeutic targets
- Developing computational methods for spatial transcriptomics data
- Developing drugs to block malaria transmission
- Developing models for prevention of hereditary ovarian cancer
- Developing statistical frameworks for analysing next generation sequencing data
- Development and mechanism of action of novel antimalarials
- Development of novel RNA sequencing protocols for gene expression analysis
- Discoveries in red blood cell production and function
- Discovering epigenetic silencing mechanisms in female stem cells
- Discovery and targeting of novel regulators of transcription
- Dissecting host cell invasion by the diarrhoeal pathogen Cryptosporidium
- Dissecting mechanisms of cytokine signalling
- Doublecortin-like kinases, drug targets in cancer and neurological disorders
- Epigenetic biomarkers of tuberculosis infection
- Epigenetics – genome wide multiplexed single-cell CUT&Tag assay development
- Exploiting cell death pathways in regulatory T cells for cancer immunotherapy
- Exploiting the cell death pathway to fight Schistosomiasis
- Finding treatments for chromatin disorders of intellectual disability
- Functional epigenomics in human B cells
- How do nutrition interventions and interruption of malaria infection influence development of immunity in sub-Saharan African children?
- Human lung protective immunity to tuberculosis
- Improving therapy in glioblastoma multiforme by activating complimentary programmed cell death pathways
- Innovating novel diagnostic tools for infectious disease control
- Integrative analysis of single cell RNAseq and ATAC-seq data
- Interaction with Toxoplasma parasites and the brain
- Interactions between tumour cells and their microenvironment in non-small cell lung cancer
- Investigation of a novel cell death protein
- Malaria: going bananas for sex
- Mapping spatial variation in gene and transcript expression across tissues
- Mechanisms of Wnt secretion and transport
- Multi-modal computational investigation of single-cell communication in metastatic cancer
- Nanoparticle delivery of antibody mRNA into cells to treat liver diseases
- Naturally acquired immune response to malaria parasites
- Organoid-based discovery of new drug combinations for bowel cancer
- Organoid-based precision medicine approaches for oral cancer
- Removal of tissue contaminations from RNA-seq data
- Reversing antimalarial resistance in human malaria parasites
- Role of glycosylation in malaria parasite infection of liver cells, red blood cells and mosquitoes
- Screening for novel genetic causes of primary immunodeficiency
- Single-cell ATAC CRISPR screening – Illuminate chromatin accessibility changes in genome wide CRISPR screens
- Spatial single-cell CRISPR screening – All in one screen: Where? Who? What?
- Statistical analysis of single-cell multi-omics data
- Structural and functional analysis of epigenetic multi-protein complexes in genome regulation
- Structural basing for Wnt acylation
- Structure, dynamics and impact of extra-chromosomal DNA in cancer
- Targeted deletion of disease-causing T cells
- Targeting cell death pathways in tissue Tregs to treat inflammatory diseases
- The cellular and molecular calculation of life and death in lymphocyte regulation
- The role of hypoxia in cell death and inflammation
- The role of ribosylation in co-ordinating cell death and inflammation
- Understanding Plasmodium falciparum invasion of red blood cells
- Understanding cellular-cross talk within a tumour microenvironment
- Understanding the genetics of neutrophil maturation
- Understanding the roles of E3 ubiquitin ligases in health and disease
- Unveiling the heterogeneity of small cell lung cancer
- Using combination immunotherapy to tackle heterogeneous brain tumours
- Using intravital microscopy for immunotherapy against brain tumours
- Using nanobodies to understand malaria invasion and transmission
- Using structural biology to understand programmed cell death
- Validation and application of serological markers of previous exposure to malaria
- School resources
- Frequently asked questions
- Student profiles
- Abebe Fola
- Andrew Baldi
- Anna Gabrielyan
- Ashley Weir
- Bridget Dorizzi
- Casey Ah-Cann
- Catia Pierotti
- Emma Nolan
- Huon Wong
- Jasmine Rou
- Jing Deng
- Joy Liu
- Kaiseal Sarson-Lawrence
- Komal Patel
- Krishneel Prasa
- Lilly Backshell
- Malvika Kharbanda
- Megan Kent
- Naomi Jones
- Pailene Lim
- Rebecca Delconte
- Roberto Bonelli
- Rune Larsen
- Runyu Mao
- Sarah Garner
- Simona Seizova
- Sophie Collard
- Wayne Cawthorne
- Wil Lehmann
- Yanxiang Meng
- Zhong Yan Gan
- Miles Horton
- Alexandra Gurzau
- Student achievements
- Student association
- Learning Hub
- News
- Donate
- Online donation
- Ways to support
- Support outcomes
- Supporter stories
- Rotarians against breast cancer
- A partnership to improve treatments for cancer patients
- 20 years of cancer research support from the Helpman family
- A generous gift from a cancer survivor
- A generous vision for impactful medical research
- A gift to support excellence in Australian medical research
- An enduring friendship
- Anonymous donor helps bridge the 'valley of death'
- Philanthropy through the power of sisterhood
- Renewed support for HIV eradication project
- Searching for solutions to muscular dystrophy
- Supporting research into better treatments for colon cancer
- Taking a single cell focus with the DROP-seq
- Donors
- WEHI.TV
Lymphoma

Lymphomas are the most common form of blood cancer in Australia, and the most common cancers diagnosed in 15-24 year olds. Lymphoma is caused by uncontrolled growth of immune cells called lymphocytes. Our research aims to improve the outcomes for people with lymphoma.
Our lymphoma research
Our lymphoma researchers are:
- Discovering the changes that transform a normal cell into a lymphoma cell.
- Demonstrating the role of the immune system in preventing lymphoma formation.
- Developing treatments that target the proteins keeping lymphoma cells alive.
- Leading clinical trials to test potential new treatment for lymphoma.
What is lymphoma?
Lymphoma is a cancer that develops from white blood cells called lymphocytes. It occurs when a lymphocyte undergoes changes that allow it to divide uncontrollably and become long-lived.
Lymphoma develops within the lymph nodes, spleen, or bone marrow, collectively called lymphoid organs. The lymphoma cells initially grow within a single lump. Over time they may spread to other parts of the body.
Lymphoma shares many similarities with some types of leukaemia.
There are many types of lymphoma. These differ in:
- The features of the lymphoma cells, such the proteins found on the outside of the cells.
- The location of the lymphoma within the body.
- How rapidly the disease advances.
- The best treatment for the particular lymphoma.
- The characteristics, such as age, of the people who are most often affected.
Research is revealing how different types of lymphoma develop. Many occur because of changes in the genetic material of certain types of lymphocytes. For example, follicular lymphoma cells contain a genetic rearrangement that increases the amount of the cell survival protein Bcl-2 in cells.
Some lymphomas are triggered by a viral infection. Some types of lymphoma are associated with Epstein-Barr virus (EBV), although most people who develop this common infection never get lymphoma. The virus introduces its own genetic material into lymphocytes. This may trigger the lymphocyte to divide uncontrollably or become long-lived.
Lymphoma Australia and the Leukaemia Foundation provide information about specific types of lymphoma.
Lymphoma risk factors
There are many factors that can contribute to a person’s risk of developing lymphoma. These include:
- Age: many types of lymphomas are more common in older people, but some types are more common at younger ages.
- Gender: different types of lymphoma are more common in men or women.
- Infection with certain viruses such as Epstein-Barr virus.
- Exposure to agents that damage DNA.
- Immune disorders including immunodeficiency and autoimmune disease.
How is lymphoma treated?
The treatment of lymphoma depends on the type of lymphoma. Factors such as how rapidly the lymphoma is growing can influence how aggressively it is treated.
Many types of lymphoma are treated with combinations of:
- Chemotherapy, using medicines to kill the dividing lymphoma cells.
- Radiation therapy, either by directing radiation beams at a tumour, or attaching radioactive particles to antibodies that bind to a tumour.
- Targeted therapies that use antibodies to bind to proteins on the surface of lymphoma cells, killing them; or small molecules that block the function of important proteins within the lymphoma cells.
- Stem cell transplant in which the person with lymphoma is treated with very high doses of radiation or chemotherapy to kill the lymphoma cells. This also kills the normal blood stem cells that are then replaced with healthy blood stem cells taken either from another person or harvested from patients themself.
For more information about lymphoma treatments, please visit Lymphoma Australia or the Leukaemia Foundation.
WEHI researchers are not able to provide specific medical advice specific to individuals. If you have cancer and wish to find out more information about clinical trials, please visit the Australian Cancer Trials or the Australian New Zealand Clinical Trials Registry, or consult your medical specialist.
Researchers:
Super Content:
Institute researchers have discovered that targeting a cell ‘survival’ protein could help treat some lymphomas, including those that are resistant to existing therapies.
In a world first, Institute scientists and collaborators have discovered a new type of anti-cancer drug that can put cancer cells into a permanent sleep, without the harmful side-effects caused by conventional cancer therapies.
Our researchers have discovered a promising strategy for treating cancers that are caused by one of the most common cancer-causing changes in cells.
Institute scientists have discovered how the most important gene in preventing human cancer, p53, is able to stop the development of blood cancers.